- Home
- AEI vs QNTM Comparison
AEI vs QNTM Comparison
Compare AEI & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- QNTM
- Stock Information
- Founded
- AEI 2014
- QNTM 1998
- Country
- AEI United States
- QNTM Canada
- Employees
- AEI N/A
- QNTM N/A
- Industry
- AEI Building operators
- QNTM
- Sector
- AEI Real Estate
- QNTM
- Exchange
- AEI Nasdaq
- QNTM NYSE
- Market Cap
- AEI 10.7M
- QNTM 35.6M
- IPO Year
- AEI N/A
- QNTM N/A
- Fundamental
- Price
- AEI $0.84
- QNTM $13.46
- Analyst Decision
- AEI
- QNTM
- Analyst Count
- AEI 0
- QNTM 0
- Target Price
- AEI N/A
- QNTM N/A
- AVG Volume (30 Days)
- AEI 94.6K
- QNTM 210.7K
- Earning Date
- AEI 05-15-2025
- QNTM 05-14-2025
- Dividend Yield
- AEI N/A
- QNTM N/A
- EPS Growth
- AEI N/A
- QNTM N/A
- EPS
- AEI N/A
- QNTM N/A
- Revenue
- AEI $16,097,995.00
- QNTM N/A
- Revenue This Year
- AEI N/A
- QNTM N/A
- Revenue Next Year
- AEI N/A
- QNTM N/A
- P/E Ratio
- AEI N/A
- QNTM N/A
- Revenue Growth
- AEI N/A
- QNTM N/A
- 52 Week Low
- AEI $0.70
- QNTM $2.70
- 52 Week High
- AEI $2.61
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- AEI 37.30
- QNTM 73.02
- Support Level
- AEI $0.77
- QNTM $10.75
- Resistance Level
- AEI $0.85
- QNTM $13.44
- Average True Range (ATR)
- AEI 0.06
- QNTM 1.39
- MACD
- AEI -0.02
- QNTM 0.22
- Stochastic Oscillator
- AEI 30.47
- QNTM 83.46
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.